Nu-Med Plus Inc., a medical device company which investigates and develops applications of nitric oxide technologies in the medical field, has selected Salient Technologies Inc. as its strategic product development partner for design of a nitric oxide delivery product for hospital use. This is the final phase for the go to market design that will be submitted to the U.S. Food and Drug Administration (FDA) for approval.
 
Salient Technologies is a creative product development firm with a team that helps leading brands and manufacturers with medical device development targeting a competitive edge in the marketplace. The company will be working with the NU-MED team moving forward toward FDA submission of its Nitric Oxide Hospital unit.
 
Inhaled nitric oxide is a medically essential gas that is presently used in neonate hypoxia therapy (inadequate oxygen level in newborns) and may have future applications for a variety of other diseases and complications that are currently being investigated.
 
“We are excited to have retained Salient Technologies as we aggressively step forward pursuing FDA clearances and approvals for our Nitric oxide products,“ said Jeff Robins, president and CEO of Nu-Med Plus.
 
Nu-Med Plus Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high-growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use. The company is based in Salt Lake City, Utah.